Hereditary nonpolyposis colorectal cancer pathophysiology

Jump to navigation Jump to search

Hereditary Nonpolyposis Colorectal Cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hereditary Nonpolyposis Colorectal Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hereditary nonpolyposis colorectal cancer pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hereditary nonpolyposis colorectal cancer pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hereditary nonpolyposis colorectal cancer pathophysiology

CDC on Hereditary nonpolyposis colorectal cancer pathophysiology

Hereditary nonpolyposis colorectal cancer pathophysiology in the news

Blogs on Hereditary nonpolyposis colorectal cancer pathophysiology

Directions to Hospitals Treating Hereditary nonpolyposis colorectal cancer

Risk calculators and risk factors for Hereditary nonpolyposis colorectal cancer pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

HNPCC is an autosomal dominant genetic disease characterized by the early onset of colon cancer, endometrial cancer, and other malignant tumors caused by genetic mutations, that lead to an accumulation of DNA mismatches in MMR gene.[1] Development of HNPCC is the result of multiple genetic mutations. Genes involved in the pathogenesis of HNPCC include; MSH-2, MLH-1, MSH-6, PMS-2 ,PMS-1, TGF-BR2, and MLH-3. This syndrome occurs mostly in the proximal colon (60% to 80%) and endometrial cancer is the most common sentinel cancer among female patients with HNPCC.[1]

Pathogenesis

HNPCC defects in DNA mismatch repair leading to microsatellite instability, also known as MSI-H, which is a hallmark of HNPCC. Three major groups of MSI-H cancers can be recognized by histopathological criteria:

MSI is identifiable in cancer specimens in the pathology laboratory. In hereditary nonpolyposis colorectal cancer, colon malignancies usually occur from a single or a few adenomas, and mostly occurs in the proximal colon.

Genetics

HNPCC is known to be associated with mutations in genes involved in the DNA mismatch repair pathway. HNPCC is inherited in an autosomal dominant manner.Therefore, most people with HNPCC inherit the condition from a parent. Families found to have a deleterious mutation in an HNPCC gene should be considered to have HNPCC regardless of the extent of the family history. However, due to incomplete penetrance, variable age of cancer diagnosis, cancer risk reduction, or early death, not all patients with an HNPCC gene mutation have a parent who had cancer. Some patients develop HNPCC de-novo in a new generation, without inheriting the gene. These patients are often only identified after developing an early-life colon cancer. Parents with HNPCC have a 50% chance to pass the gene on to each child.

Development of HNPCC is the result of multiple genetic mutations.[1] Genes involved in the pathogenesis of HNPCC include:

OMIM name Genes implicated in HNPCC Frequency of mutations in HNPCC families Locus First publication
HNPCC1 (120435) MSH2 approximately 60% 2p22 Fishel 1993[2]
HNPCC2 (609310) MLH1 approximately 30% 3p21 Papadopoulos 1994[3]
HNPCC5 MSH6 7-10% 2p16 Miyaki 1997[4]
HNPCC4 PMS2 relatively infrequent 7p22 [5] Nicolaides 1994
HNPCC3 PMS1 case report[6] 2q31-q33 Nicolaides 1994
HNPCC6 TGFBR2 case report[7] 3p22
HNPCC7 MLH3 disputed[8] 14q24.3


HNPCC is inherited in an autosomal dominant fashion.


Associated Conditions

Gross Pathology

On gross pathology, there are no characteristic findings of HNPCC.Closing </ref> missing for <ref> tag

Gallery

  • Micrograph of a sebaceous adenoma, as may be seen in Muir-Torre syndrome.
    Micrograph of a sebaceous adenoma, as may be seen in Muir-Torre syndrome.

References

  1. ↑ 1.0 1.1 1.2 Si JW, Wang L, Ba XJ, Zhang X, Dong Y, Zhang JX, Li WT, Li T (2015). "[Clinicopathological screening of Lynch syndrome: a report of 2 cases and literature review]". Beijing Da Xue Xue Bao (in Chinese). 47 (5): 858–64. PMID 26474631.
  2. ↑ Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R (Dec 1993). "The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer". Cell. 75 (5): 1027–38. doi:10.1016/0092-8674(93)90546-3. PMID 8252616.
  3. ↑ Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD (Mar 1994). "Mutation of a mutL homolog in hereditary colon cancer". Science. 263 (5153): 1625–9. doi:10.1126/science.8128251. PMID 8128251.
  4. ↑ Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T (Nov 1997). "Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer". Nature Genetics. 17 (3): 271–2. doi:10.1038/ng1197-271. PMID 9354786.
  5. ↑ Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM (Sep 1994). "Mutations of two PMS homologues in hereditary nonpolyposis colon cancer". Nature. 371 (6492): 75–80. doi:10.1038/371075a0. PMID 8072530.
  6. ↑ Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM (Sep 1994). "Mutations of two PMS homologues in hereditary nonpolyposis colon cancer". Nature. 371 (6492): 75–80. doi:10.1038/371075a0. PMID 8072530.
  7. ↑ Lu SL, Kawabata M, Imamura T, Akiyama Y, Nomizu T, Miyazono K, Yuasa Y (May 1998). "HNPCC associated with germline mutation in the TGF-beta type II receptor gene". Nature Genetics. 19 (1): 17–8. doi:10.1038/ng0598-17. PMID 9590282.
  8. ↑ Ou J, Rasmussen M, Westers H, Andersen SD, Jager PO, Kooi KA, Niessen RC, Eggen BJ, Nielsen FC, Kleibeuker JH, Sijmons RH, Rasmussen LJ, Hofstra RM (Apr 2009). "Biochemical characterization of MLH3 missense mutations does not reveal an apparent role of MLH3 in Lynch syndrome". Genes, Chromosomes & Cancer. 48 (4): 340–50. doi:10.1002/gcc.20644. PMID 19156873.
  9. ↑ Okuda T, Sekizawa A, Purwosunu Y; et al. (2010). "Genetics of endometrial cancers". Obstet Gynecol Int. 2010: 984013. doi:10.1155/2010/984013. PMC 2852605. PMID 20396392.
  10. ↑ Garg, K.; Soslow, RA. (2009). "Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma". J Clin Pathol. 62 (8): 679–84. doi:10.1136/jcp.2009.064949. PMID 19638537. Unknown parameter |month= ignored (help)
  11. ↑ Lax, SF. (2002). "[Dualistic model of molecular pathogenesis in endometrial carcinoma]". Zentralbl Gynakol. 124 (1): 10–6. doi:10.1055/s-2002-20303. PMID 11873308. Unknown parameter |month= ignored (help)
  12. ↑ Garg, K.; Soslow, RA. (2009). "Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma". J Clin Pathol. 62 (8): 679–84. doi:10.1136/jcp.2009.064949. PMID 19638537. Unknown parameter |month= ignored (help)
  13. ↑ 13.0 13.1 13.2 13.3 Online Mendelian Inheritance in Man (OMIM) 120435
  14. ↑ Cristofaro, G.; Lynch, HT.; Caruso, ML.; Attolini, A.; DiMatteo, G.; Giorgio, P.; Senatore, S.; Argentieri, A.; Sbano, E. (1987). "New phenotypic aspects in a family with Lynch syndrome II". Cancer. 60 (1): 51–8. PMID 3581033. Unknown parameter |month= ignored (help)
  15. ↑ Barrow, E.; Robinson, L.; Alduaij, W.; Shenton, A.; Clancy, T.; Lalloo, F.; Hill, J.; Evans, DG. (2009). "Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations". Clin Genet. 75 (2): 141–9. doi:10.1111/j.1399-0004.2008.01125.x. PMID 19215248. Unknown parameter |month= ignored (help)
  16. ↑ Renkonen-Sinisalo, L.; Sipponen, P.; Aarnio, M.; Julkunen, R.; Aaltonen, LA.; Sarna, S.; Järvinen, HJ.; Mecklin, JP. (2002). "No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer". Scand J Gastroenterol. 37 (5): 574–7. PMID 12059060. Unknown parameter |month= ignored (help)
  17. ↑ Crockett, DG.; Wagner, DG.; Holmäng, S.; Johansson, SL.; Lynch, HT. (2011). "Upper urinary tract carcinoma in Lynch syndrome cases". J Urol. 185 (5): 1627–30. doi:10.1016/j.juro.2010.12.102. PMID 21419447. Unknown parameter |month= ignored (help)
  18. ↑ 18.0 18.1 Hartmann, A.; Dietmaier, W.; Hofstädter, F.; Burgart, LJ.; Cheville, JC.; Blaszyk, H. (2003). "Urothelial carcinoma of the upper urinary tract: inverted growth pattern is predictive of microsatellite instability". Hum Pathol. 34 (3): 222–7. doi:10.1053/hupa.2003.22. PMID 12673555. Unknown parameter |month= ignored (help)
  19. ↑ van der Post, RS.; Kiemeney, LA.; Ligtenberg, MJ.; Witjes, JA.; Hulsbergen-van de Kaa, CA.; Bodmer, D.; Schaap, L.; Kets, CM.; van Krieken, JH. (2010). "Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers". J Med Genet. 47 (7): 464–70. doi:10.1136/jmg.2010.076992. PMID 20591884. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Hereditary_nonpolyposis_colorectal_cancer_pathophysiology&oldid=1199820"